Skip to main content
Clinical Trials/NL-OMON46099
NL-OMON46099Not yet recruitingPhase 2

Improving treatment of right ventricular failure in pulmonary hypertension patients. - Improving treatment of RVF in PH patients.

Vrije Universiteit Medisch Centrum0 sites20 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Not yet recruiting
Enrollment
20

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • In order to be eligible to participate in this study, a subject must meet all of the following criteria:
  • Patients should be diagnosed with pre-capillary pulmonary hypertension either PAH or CTEPH, have clinical signs of decompensated right heart failure, and needing hospital - or ICU admission for IV diuretics.
  • PAH (group 1 and 1*) or CTEPH (group 2), diagnosed according ESC/ERS guidelines;
  • o Mean Pulmonary Artery Pressure (mPAP) >= 25 mmHg
  • o Pulmonary Arterial Wedge Pressure (PCWP) <15 mmHg
  • o Other possible causes of PH are excluded
  • 18-70 years old
  • Increased body weight despite increased dose diuretics in past month
  • Clinical signs of decompensation: ankle edema and/or ascites
  • eGFR; 30 ml/min/1.73m2
  • Sinusrhythm

Exclusion Criteria

  • A potential subject who meets any of the following criteria will be excluded from participation in this study:
  • Pulmonary hypertension due to connective tissue disease, and PH due to left heart disease (group 2).
  • Hypoxia defined as SaO2 <=80% and/or <= 90% with oxygen suppletion.
  • Pregnancy, lactation
  • Anuria (urine production <50 ml/day)
  • Known intolerance of loop diuretics or terlipressin
  • Recent diagnosis (<1 month ago) of acute pulmonary embolism
  • Underlying infectious disorder/ bacteremia
  • Known history of occlusive arterial disease (e.g. coronary artery disease) and/or peripheral artery disease, exception: pulmonary embolism
  • Type 1 and type 2 diabetes mellitus
  • Chronic use of NSAIDs
  • Pre-existing renal failure from other causes than forward failure (eg diabetes)

Investigators

Similar Trials